Boston Scientific Corporation (NYSE:BSX) EVP Timothy A. Pratt sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $28.22, for a total value of $282,200.00. Following the completion of the sale, the executive vice president now owns 164,681 shares in the company, valued at $4,647,297.82. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Boston Scientific Corporation (BSX) opened at $27.86 on Friday. The company has a market cap of $37.68 billion, a PE ratio of 22.49, a PEG ratio of 2.12 and a beta of 1.00. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58.

Boston Scientific Corporation (NYSE:BSX) last issued its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.31. Boston Scientific Corporation had a return on equity of 23.60% and a net margin of 9.55%. The firm had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.21 billion. During the same period in the previous year, the company posted $0.27 earnings per share. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. equities analysts forecast that Boston Scientific Corporation will post 1.25 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Timothy A. Pratt Sells 10,000 Shares of Boston Scientific Corporation (BSX) Stock” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/timothy-a-pratt-sells-10000-shares-of-boston-scientific-corporation-bsx-stock/1677634.html.

BSX has been the topic of several analyst reports. BidaskClub cut Boston Scientific Corporation from a “hold” rating to a “sell” rating in a research report on Saturday, August 26th. Stifel Nicolaus reiterated a “buy” rating and set a $32.00 price target on shares of Boston Scientific Corporation in a research report on Monday, September 25th. BMO Capital Markets lifted their price target on Boston Scientific Corporation from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Friday, October 27th. Oppenheimer Holdings, Inc. set a $29.00 price target on Boston Scientific Corporation and gave the company a “hold” rating in a research report on Friday, July 28th. Finally, Royal Bank Of Canada reiterated a “buy” rating and set a $31.00 price target on shares of Boston Scientific Corporation in a research report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $30.77.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Acrospire Investment Management LLC boosted its holdings in Boston Scientific Corporation by 157.3% during the second quarter. Acrospire Investment Management LLC now owns 5,071 shares of the medical equipment provider’s stock valued at $141,000 after purchasing an additional 3,100 shares in the last quarter. Bronfman E.L. Rothschild L.P. boosted its holdings in Boston Scientific Corporation by 14.3% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 5,761 shares of the medical equipment provider’s stock valued at $160,000 after purchasing an additional 720 shares in the last quarter. San Francisco Sentry Investment Group CA acquired a new stake in Boston Scientific Corporation during the second quarter valued at approximately $191,000. Ironwood Investment Counsel LLC acquired a new stake in Boston Scientific Corporation during the third quarter valued at approximately $204,000. Finally, Perkins Capital Management Inc. acquired a new stake in Boston Scientific Corporation during the third quarter valued at approximately $204,000. Hedge funds and other institutional investors own 90.47% of the company’s stock.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Insider Buying and Selling by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.